Compare · RMD vs SINT
RMD vs SINT
Side-by-side comparison of ResMed Inc. (RMD) and SiNtx Technologies Inc. (SINT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and SINT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $32.03B, about 3145.9x SINT ($10.2M).
- Both names hit the wire about 2 times in the past 4 weeks.
- RMD has more recent analyst coverage (25 ratings vs 1 for SINT).
- Company
- ResMed Inc.
- SiNtx Technologies Inc.
- Price
- -
- -
- Market cap
- $32.03B
- $10.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 2
- 2
- Recent ratings
- 25
- 1
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
SiNtx Technologies Inc.
Sintx Technologies, Inc., an advanced materials company, researches, develops, manufactures, and commercializes silicon nitride ceramics in the United States, Europe, and South America. It offers ceramic based solutions for various medical, industrial, and antipathogenic applications. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products. It has a collaboration agreement with Oxford Performance Materials, Inc. to develop a poly-ether-ketone-ketone silicon nitride composite based on OXPEKK SC solution casting technology. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies, Inc. in October 2018. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
Latest RMD
- Analyst initiated coverage on ResMed
- SEC Form 4 filed by Farrell Michael J.
- SEC Form 4 filed by Sandercock Brett
- SEC Form 4 filed by Farrell Peter C
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,252,902 worth of ResMed Common Stock (4,991 units at $251.03) (SEC Form 4)
- Director Farrell Peter C sold $520,440 worth of ResMed Common Stock (2,000 units at $260.22), decreasing direct ownership by 3% to 62,773 units (SEC Form 4)
- SEC Form 144 filed by ResMed Inc.
Latest SINT
- SEC Form 4 filed by Elmore Robert Ryan
- H.C. Wainwright initiated coverage on SINTX Technologies with a new price target
- SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution
- SEC Form 10-K filed by SiNtx Technologies Inc.
- SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant
- SEC Form 4 filed by SiNtx Technologies Inc.
- Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)
- Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)
- Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)
- SiNtx Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits